Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics third quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference call is being recorded today, October 22, 2025. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Leon, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, October 22, 2025, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings for the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lynn for his initial comments.

Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today we'll review our financial results for the third quarter and nine months ended September 30th, 2025, and review recent progress with our development programs and operations. The third quarter was a busy and productive time for Viking. The early part of the quarter was focused on ramping up our Phase III Vanquish Obesity program, evaluating VK2735, are dual agonists of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. Later in the quarter, we were excited to announce positive top-line results from a Phase II clinical trial of the oral tablet formulation of VK2735 in patients with obesity. This trial, called the Venture Oral Dosing Trial, successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. The study also showed VK2735 treatment to be safe and well tolerated through 13 weeks of daily dosing, with the majority of treatment emergent adverse events categorized as mild or moderate. In addition to the third quarter clinical activities, we recently announced the initiation of a clinical study to evaluate maintenance dosing with VK2735. This novel study will assess weight loss maintenance using monthly subcutaneous dosing, daily oral dosing, or weekly oral dosing. I'll have additional comments on our operations and development activities following a review of our third quarter and nine-month financial results. For that, I'll turn the call over to Greg Zanti, Vikings Chief Financial Officer.